Peptide LexiconAll compounds

Peptides for Focus and Mood: The Russian Compounds and the Evidence Problem

Semax, Selank, Cerebrolysin and Dihexa. Most of the nootropic peptides come from one research tradition — and that shapes what the evidence can tell you.

Caroline S · Published 2026-09-07

Illustration: A clear glass flask with deep green liquid and an empty copper tube on a white lab bench.
Illustration

One pattern explains most of this category

Almost every peptide discussed for focus and mood comes from one research tradition: Russian and post-Soviet peptide pharmacology, with decades of work, its own institutions, and its own literature.

Semax, Selank, the epitalon-adjacent preparations, and the clinical use of Cerebrolysin all sit inside it.

That fact does more to explain the evidence in this category than anything about the individual compounds.

Why it matters, and what it does not mean

It does not mean Russian research is unreliable. It is a real field with real institutions and a long history.

What it means is that the ordinary cross-check has largely not happened. A result carries weight when someone with no stake in it, working under different incentives, looks for the same thing and finds it. These compounds have substantial home literatures and limited independent replication in Western trials.

A reader weighing a claim is entitled to know which kind of evidence sits behind it. That is not scepticism about the origin; it is the same standard applied to any compound whose literature comes mostly from the people who developed it — which is also the situation with epitalon, and would be a caveat wherever it occurred.

The compounds

Semax and Selank are the two most discussed, both usually sold as nasal sprays. Selank was designed as an anxiolytic intended to avoid the sedation and dependence of benzodiazepines; Semax is used in Russia for cognitive and neurological indications. Both are unapproved in the United States and the EU, and both appear on the FDA's compounding page among withdrawn nominations rather than on the current Category 2 list.

Cerebrolysin is different in an instructive way. It is genuinely licensed and widely prescribed in Russia, Eastern Europe and China — and it is also the compound here with the most independent evidence, because Cochrane has assessed it.

That assessment, across seven randomised trials and 1,773 participants with acute ischaemic stroke, found at moderate certainty probably no beneficial effect on preventing death from any cause, and a potential increase in non-fatal serious adverse events. Three of the seven trials were manufacturer-supported. A separate review of vascular dementia found inconsistent results.

So the compound in this category with the most clinical use also has the most discouraging independent evidence. That is worth sitting with, because it is roughly the opposite of what the category's marketing implies.

Dihexa is the outlier — American in origin, and sold on preclinical potency figures rather than clinical use. Those figures describe how strongly it engages its target in a cell assay. There is no published human trial evidence at all, so the entire distance between a striking laboratory number and a useful effect in a person is unexamined.

What each entry says

Last checked

2026-09-07.

Frequently asked questions

Which peptides are used for focus and mood?

Semax and Selank are the two most discussed, both developed in Russia and both usually sold as nasal sprays. Cerebrolysin is used for cognitive indications in several countries. Dihexa appears in the same conversations on the strength of preclinical potency claims.

Why does it matter that these compounds are Russian?

Not because Russian research is unreliable — it is a real field with real institutions. It matters because the ordinary cross-check that gives a result its weight has largely not happened. These compounds have substantial home literatures spanning decades, and limited replication by unconnected groups working under different incentives and publishing in different journals. A reader deciding how much confidence to place in a claim is entitled to know whether it has been confirmed by anyone with no stake in it.

Does cerebrolysin work?

The largest independent assessment is a Cochrane review of seven randomised trials in 1,773 people with acute ischaemic stroke. It found, at moderate certainty, probably no beneficial effect on preventing death from any cause, and a potential increase in non-fatal serious adverse events. Three of the seven trials were manufacturer-supported. A separate Cochrane review of vascular dementia found inconsistent results.

What about dihexa's potency claims?

The figures come from preclinical work and describe how strongly the compound engages its target in a cell assay. That is not the same as helping anyone. No published human trial evidence exists for dihexa, so the entire distance between a striking laboratory number and a useful effect in a person is unexamined.

Is any of this approved?

No peptide is an approved treatment in the United States for cognition, focus or mood in a healthy person. Cerebrolysin is licensed for cognitive indications in a number of other countries, which is a genuine difference — and also the compound with the most discouraging independent evidence on this page.